Premium
Continuing olanzapine with sertraline reduces relapse in psychotic depression
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30503
Subject(s) - olanzapine , sertraline , medicine , depression (economics) , adverse effect , placebo , antipsychotic , psychiatry , schizophrenia (object oriented programming) , psychology , anxiety , alternative medicine , antidepressant , macroeconomics , economics , pathology
Continuation of olanzapine treatment for 36 weeks after response to combined treatment with olanzapine and sertraline in patients with psychotic depression reduced the risk of relapse to this severely disabling condition, a placebo‐controlled trial has found. The continued use of olanzapine was associated with weight gain, however, which researchers said highlights the need to balance the potential benefits of the atypical antipsychotic against the risk of adverse effects. Study results were published in the Aug. 20 issue of JAMA .